ArticleAnatolian journal of cardiology2016
Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera.
Article in Anatolian journal of cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Trends and Outcomes Following Percutaneous Coronary Intervention in Patients With Myeloproliferative Neoplasms: Insights From National Database.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Article
- Primary polycythaemia: A neglected risk factor.Journal of family medicine and primary care · 2024Article
- Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm.World journal of cardiology · 2024Article
- Acute myocardial infarction in myeloproliferative neoplasms.World journal of cardiology · 2023Review
- Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA): Focus on Coronary Microvascular Dysfunction and Genetic Susceptibility.Journal of clinical medicine · 2023Review
- Article
- Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.Leukemia · 2021Review
- Percutaneous coronary intervention in a patient with heparin resistance due to essential thrombocythaemia: a case report.European heart journal. Case reports · 2021Article
- Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis.Molecular biology reports · 2020Review
- Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm.The Journal of clinical investigation · 2020Article
- Atypical Myocardial Infarction with Apical Thrombus and Systemic Embolism: A Rare Presentation of Likely JAK2 V617F-Positive Myeloproliferative Neoplasm.Case reports in oncological medicine · 2020Article
- A case of simultaneous acute cardio-cerebral infarction in a woman with essential thrombocythemia.The Journal of international medical research · 2019Article
- Essential thrombocythemia presenting as acute coronary syndrome: case reports and literature review.Journal of thrombosis and thrombolysis · 2017Review
- Myocardial infarction as a thrombotic complication of myeloproliferative disorders.Anatolian journal of cardiology · 2016Article
- Acute Coronary Syndrome in Essential Thrombocythemia and Polycythemia Vera.Heart views : the official journal of the Gulf Heart AssociationReview
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDetailed analyses of clinical characteristics of myocardial infarction (MI) as an essential thrombocythemia (ET)- and polycythemia vera (PV)-related complication have been so far presented mostly as case reports. Therefore, the aim of this retrospective analysis was to evaluate the main cardiological and hematological characteristics for better understanding myocardial complications in ET/PV.
methodsA retrospective analysis was carried out involving 263 patients diagnosed with ET or PV (155/108) between 1998 and 2014. Fourteen patients suffered MI during the hematological follow-up. Their clinical characteristics were compared to 162 patients (97 ET and 65 PV patients) who did not exhibit any major thrombotic complications (MI, stroke/transient ischemic attack, and venous events) before or after hematological diagnosis of ET/PV.
resultsFourteen MI events occurred among the 263 patients (5.3%). Vascular risk factors were found in 92.9% (13/14) of analyzed cases. In all, 71.4% of the MI complications developed within 12 months after the diagnosis of ET/PV. The coronary angiography findings revealed ST-elevation MI in four cases and non-ST-elevation MI in 10. Significant stenosis of coronary arteries requiring percutaneous coronary intervention with a stent implantation was present in seven cases, while three had complex stenoses or previous grafts/stents. All of them had undergone coronary artery bypass graft operations.
conclusionThe results of the present study suggest that early detection and consideration of individual management of vascular risk factors in ET/PV patients are also important. Furthermore, a better theoretic understanding of platelet activation and role of leukocytes in myeloproliferative neoplasm-related thrombosis could open new perspectives in thrombosis prediction and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.